Therapeutic potential of endogenous hydrogen sulfide inhibition in breast cancer (Review)

Li,Ming; Liu,Ya; Deng,Yuying; Pan,Limin; Fu,Han; Han,Xue; Li,Yuxi; Shi,Haimei; Wang,Tianxiao

doi:10.3892/or.2021.8019

Therapeutic potential of endogenous hydrogen sulfide inhibition in breast cancer (Review)

Authors:
- Ming Li
- Ya Liu
- Yuying Deng
- Limin Pan
- Han Fu
- Xue Han
- Yuxi Li
- Haimei Shi
- Tianxiao Wang
View Affiliations

Affiliations: School of Pharmacy, Henan University, Kaifeng, Henan 475004, P.R. China, Department of Anesthesiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: March 19, 2021 https://doi.org/10.3892/or.2021.8019
Article Number: 68
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hydrogen sulfide (H₂S), the third gas signal molecule, is associated with the modulation of various physiological and pathological processes. Recent studies have reevealed that endogenous H₂S may promote proliferation, induce angiogenesis and inhibit apoptosis, thereby stimulating oncogenesis. Conversely, decreased endogenous H₂S release suppresses growth of various tumors including breast cancer. This observation suggests an alternative tumor therapy strategy by inhibiting H₂S‑producing enzymes to reduce the release of endogenous H₂S. Breast cancer is the most common type of cancer in women. Due to the lack of approved targeted therapy, its recurrence and metastasis still affect its clinical treatment. In recent years, significant progress has been made in the control of breast cancer by using inhibitors on H₂S‑producing enzymes. This review summarized the roles of endogenous H₂S‑producing enzymes in breast cancer and the effects of the enzyme inhibitors on anticancer and anti‑metastasis, with the aim of providing new insights for the treatment of breast cancer.

View Figures

View References

1	Szabo C: Gaseotransmitters: New frontiers for translational science. Sci Transl Med. 2:59ps542010. View Article : Google Scholar : PubMed/NCBI
2	Kabil O and Banerjee R: Enzymology of H2S biogenesis, decay and signaling. Antioxid Redox Signal. 20:770–782. 2014. View Article : Google Scholar : PubMed/NCBI
3	Kimura H: Hydrogen sulfide: Its production, release and functions. Amino Acids. 41:113–121. 2011. View Article : Google Scholar : PubMed/NCBI
4	Mani S, Untereiner A, Wu L and Wang R: Hydrogen sulfide and the pathogenesis of atherosclerosis. Antioxid Redox Signal. 20:805–817. 2014. View Article : Google Scholar : PubMed/NCBI
5	Wu D, Wang J, Li H, Xue M, Ji A and Li Y: Role of hydrogen sulfifide in ischemia-reperfusion injury. Oxid Med Cell Longev. 2015:1869082015. View Article : Google Scholar : PubMed/NCBI
6	Szabó C: Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov. 6:917–935. 2007. View Article : Google Scholar : PubMed/NCBI
7	Wang R: Physiological implications of hydrogen sulfide: A whiff exploration that blossomed. Physiol Rev. 92:791–896. 2012. View Article : Google Scholar : PubMed/NCBI
8	Fagone P, Mazzon E, Bramanti P, Bendtzen K and Nicoletti F: Gasotransmitters and the immune system: Mode of action and novel therapeutic targets. Eur J Pharmacol. 834:92–102. 2018. View Article : Google Scholar : PubMed/NCBI
9	Mintz J, Vedenko A, Rosete O, Shah K, Goldstein G, Hare JM, Ramasamy R and Arora H: Current advances of nitric oxide in cancer and anticancer therapeutics. Vaccines (Basel). 9:942021. View Article : Google Scholar : PubMed/NCBI
10	Motterlini R and Otterbein LE: The therapeutic potential of carbon monoxide. Nat Rev Drug Discov. 9:728–743. 2010. View Article : Google Scholar : PubMed/NCBI
11	Lazarević M, Battaglia G, Jevtić B, Đedović N, Bruno V, Cavalli E, Miljković Đ, Nicoletti F, Momčilović M and Fagone P: Upregulation of tolerogenic pathways by the hydrogen sulfide donor GYY4137 and impaired expression of H₂S-producing enzymes in multiple sclerosis. Antioxidants (Basel). 9:6082020. View Article : Google Scholar
12	Lazarević M, Mazzon E, Momčilović M, Basile MS, Colletti G, Petralia MC, Bramanti P, Nicoletti F and Miljković Đ: The H₂S donor GYY4137 stimulates reactive oxygen species generation in BV2 cells while suppressing the secretion of TNF and nitric oxide. Molecules. 23:29662018. View Article : Google Scholar
13	Gao L and Williams JL: Nitric oxide-donating aspirin induces G2/M phase cell cycle arrest in human cancer cells by regulating phase transition proteins. Int J Oncol. 41:325–330. 2012.PubMed/NCBI
14	Furuhashi S, Sugita H, Takamori H, Horino K, Nakahara O, Okabe H, Miyake K, Tanaka H, Beppu T and Baba H: NO donor and MEK inhibitor synergistically inhibit proliferation and invasion of cancer cells. Int J Oncol. 40:807–815. 2012.PubMed/NCBI
15	McMurtry V, Saavedra JE, Nieves-Alicea R, Simeone AM, Keefer LK and Tari AM: JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells. Int J Oncol. 38:963–971. 2011.PubMed/NCBI
16	Maksimovic-Ivanic D, Fagone P, McCubrey J, Bendtzen K, Mijatovic S and Nicoletti F: HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives? Int J Cancer. 140:1713–1726. 2017. View Article : Google Scholar : PubMed/NCBI
17	Rothweiler F, Michaelis M, Brauer P, Otte J, Weber K, Fehse B, Doerr HW, Wiese M, Kreuter J, Al-Abed Y, et al: Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia. 12:1023–1030. 2010. View Article : Google Scholar : PubMed/NCBI
18	Nikolic I, Saksida T, Mangano K, Vujicic M, Stojanovic I, Nicoletti F and Stosic-Grujicic S: Pharmacological application of carbon monoxide ameliorates islet-directed autoimmunity in mice via anti-inflammatory and anti-apoptotic effects. Diabetologia. 57:980–990. 2014. View Article : Google Scholar : PubMed/NCBI
19	Fagone P, Mangano K, Coco M, Perciavalle V, Garotta G, Romao CC and Nicoletti F: Therapeutic potential of carbon monoxide in multiple sclerosis. Clin Exp Immunol. 167:179–187. 2012. View Article : Google Scholar : PubMed/NCBI
20	Fagone P, Mangano K, Quattrocchi C, Motterlini R, Di Marco R, Magro G, Penacho N, Romao CC and Nicoletti F: Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1. Clin Exp Immunol. 163:368–374. 2011. View Article : Google Scholar : PubMed/NCBI
21	Módis K, Wolanska K and Vozdek R: Hydrogen sulfide in cell signaling, signal transduction, cellular bioenergetics and physiology in C. elegans. Gen Physiol Biophys. 32:1–22. 2013. View Article : Google Scholar : PubMed/NCBI
22	Wallace JL, Ferraz JG and Muscara MN: Hydrogen sulfide: An endogenous mediator of resolution of inflammation and injury. Antioxid Redox Signal. 17:58–67. 2012. View Article : Google Scholar : PubMed/NCBI
23	Wu D, Si W, Wang M, Lv S, Ji A and Li Y: Hydrogen sulfide in cancer: Friend or foe? Nitric Oxide. 50:38–45. 2015. View Article : Google Scholar : PubMed/NCBI
24	Ngowi EE, Afzal A, Sarfraz M, Khattak S, Zaman SU, Khan NH, Li T, Jiang QY, Zhang X, Duan SF, et al: Role of hydrogen sulfide donors in cancer development and progression. Int J Biol Sci. 17:73–88. 2021. View Article : Google Scholar : PubMed/NCBI
25	Lee ZW, Zhou J, Chen CS, Zhao Y, Tan CH, Li L, Moore PK and Deng LW: The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One. 6:e210772011. View Article : Google Scholar : PubMed/NCBI
26	Lu S, Gao Y, Huang X and Wang X: GYY4137, a hydrogen sulfide (H₂S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway. Int J Oncol. 44:1259–1267. 2014. View Article : Google Scholar : PubMed/NCBI
27	Sonke E, Verrydt M, Postenka CO, Pardhan S, Willie CJ, Mazzola CR, Hammers MD, Pluth MD, Lobb I, Power NE, et al: Inhibition of endogenous hydrogen sulfide production in clear-cell renal cell carcinoma cell lines and xenografts restricts their growth, survival and angiogenic potential. Nitric Oxide. 49:26–39. 2015. View Article : Google Scholar : PubMed/NCBI
28	Oláh G, Módis K, Törö G, Hellmich MR, Szczesny B and Szabo C: Role of endogenous and exogenous nitric oxide, carbon monoxide and hydrogen sulfide in HCT116 colon cancer cell proliferation. Biochem Pharmacol. 149:186–204. 2018. View Article : Google Scholar : PubMed/NCBI
29	Hellmich MR and Szabo C: Hydrogen sulfide and cancer. Handb Exp Pharmacol. 230:233–241. 2015. View Article : Google Scholar : PubMed/NCBI
30	Dilek N, Papapetropoulos A, Toliver-Kinsky T and Szabo C: Hydrogen sulfide: An endogenous regulator of the immune system. Pharmacol Res. 161:1051192020. View Article : Google Scholar : PubMed/NCBI
31	Szabo C: Hydrogen sulfide, an endogenous stimulator of mitochondrial function in cancer cells cells. Cells. 10:2202021. View Article : Google Scholar : PubMed/NCBI
32	Jhee KH and Kruger WD: The role of cystathionine beta-synthase in homocysteine metabolism. Antioxid Redox Signal. 7:813–822. 2005. View Article : Google Scholar : PubMed/NCBI
33	Zhu H, Blake S, Chan KT, Pearson RB and Kang J: Cystathionine β-synthase in physiology and cancer. Biomed Res Int. 2018:32051252018. View Article : Google Scholar : PubMed/NCBI
34	Ereño-Orbea J, Majtan T, Oyenarte I, Kraus JP and Martínez-Cruz LA: Structural basis of regulation and oligomerization of human cystathionine β-synthase, the central enzyme of transsulfuration. Proc Natl Acad Sci USA. 110:E3790–E3799. 2013. View Article : Google Scholar : PubMed/NCBI
35	Taoka S and Banerjee R: Characterization of NO binding to human cystathionine beta-synthase: Possible implications of the effects of CO and NO binding to the human enzyme. J Inorg Biochem. 87:245–251. 2001. View Article : Google Scholar : PubMed/NCBI
36	Niu WN, Yadav PK, Adamec J and Banerjee R: S-glutathionylation enhances human cystathionine β-synthase activity under oxidative stress conditions. Antioxid Redox Signal. 22:350–361. 2015. View Article : Google Scholar : PubMed/NCBI
37	Renga B: Hydrogen sulfide generation in mammals: The molecular biology of cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CSE). Inflamm Allergy Drug Targets. 10:85–91. 2011. View Article : Google Scholar : PubMed/NCBI
38	Szabo C, Coletta C, Chao C, Módis K, Szczesny B, Papapetropoulos A and Hellmich MR: Tumor-derived hydrogen sulfide, produced by cystathionine-β-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proc Natl Acad Sci USA. 110:12474–12479. 2013. View Article : Google Scholar : PubMed/NCBI
39	Phillips CM, Zatarain JR, Nicholls ME, Porter C, Widen SG, Thanki K, Johnson P, Jawad MU, Moyer MP, Randall JW, et al: Upregulation of cystathionine-β-synthase in colonic epithelia reprograms metabolism and promotes carcinogenesis. Cancer Res. 77:5741–5754. 2017. View Article : Google Scholar : PubMed/NCBI
40	Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, et al: Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One. 8:e791672013. View Article : Google Scholar : PubMed/NCBI
41	Guo H, Gai JW, Wang Y, Jin HF, Du JB and Jin J: Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells. Urology. 79:483.e1–e5. 2012. View Article : Google Scholar
42	Chiku T, Padovani D, Zhu W, Singh S, Vitvitsky V and Banerjee R: H2S biogenesis by human cystathionine gamma-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia. J Biol Chem. 284:11601–11612. 2009. View Article : Google Scholar : PubMed/NCBI
43	Messerschmidt A, Worbs M, Steegborn C, Wahl MC, Huber R, Laber B and Clausen T: Determinants of enzymatic specificity in the Cys-Met-metabolism PLP-dependent enzymes family: Crystal structure of cystathionine gamma-lyase from yeast and intrafamiliar structure comparison. Biol Chem. 384:373–386. 2003. View Article : Google Scholar : PubMed/NCBI
44	Mikami Y, Shibuya N, Ogasawara Y and Kimura H: Hydrogen sulfide is produced by cystathionine γ-lyase at the steady-state low intracellular Ca(2+) concentrations. Biochem Biophys Res Commun. 431:131–135. 2013. View Article : Google Scholar : PubMed/NCBI
45	Cheung SH, Kwok WK, To KF and Lau JY: Anti-atherogenic effect of hydrogen sulfide by over-expression of cystathionine gamma-lyase (CSE) gene. PLoS One. 9:e1130382014. View Article : Google Scholar : PubMed/NCBI
46	Yuan S, Yurdagul A Jr, Peretik JM, Alfaidi M, Al Yafeai Z, Pardue S, Kevil CG and Orr AW: Cystathionine γ-lyase modulates flow-dependent vascular remodeling. Arterioscler Thromb Vasc Biol. 38:2126–2136. 2018. View Article : Google Scholar : PubMed/NCBI
47	Ivanciuc T, Sbrana E, Casola A and Garofalo RP: Cystathionine γ-lyase deficiency enhances airway reactivity and viral-induced disease in mice exposed to side-stream tobacco smoke. Pediatr Res. 86:39–46. 2019. View Article : Google Scholar : PubMed/NCBI
48	Mani S, Li H, Untereiner A, Wu L, Yang G, Austin RC, Dickhout JG, Lhoták Š, Meng QH and Wang R: Decreased endogenous production of hydrogen sulfide accelerates atherosclerosis. Circulation. 127:2523–2534. 2013. View Article : Google Scholar : PubMed/NCBI
49	Pan LL, Liu XH, Gong QH, Yang HB and Zhu YZ: Role of cystathionine γ-lyase/hydrogen sulfide pathway in cardiovascular disease: A novel therapeutic strategy? Antioxid Redox Signal. 17:106–118. 2012. View Article : Google Scholar : PubMed/NCBI
50	Fu X, Zhou K, Gao Q, Zheng S, Chen H, Li P, Zhang Y, Suo K, Simoncini T and Wang T: 17β-estradiol attenuates atherosclerosis development: The possible role of hydrogen sulfide. Int J Cardiol. 167:1061–1063. 2013. View Article : Google Scholar : PubMed/NCBI
51	Lambertini E, Penolazzi L, Angelozzi M, Grassi F, Gambari L, Lisignoli G, De Bonis P, Cavallo M and Piva R: The expression of cystathionine gamma-lyase is regulated by estrogen receptor alpha in human osteoblasts. Oncotarget. 8:101686–101696. 2017. View Article : Google Scholar : PubMed/NCBI
52	Xu X, Yan Q, Liu X, Li P, Li X, Chen Y, Simoncini T, Liu J, Zhu D and Fu X: 17β-Estradiol nongenomically induces vascular endothelial H₂S release by promoting phosphorylation of cystathionine γ-lyase. J Biol Chem. 294:15577–15592. 2019. View Article : Google Scholar : PubMed/NCBI
53	You J, Shi X, Liang H, Ye J, Wang L, Han H, Fang H, Kang W and Wang T: Cystathionine-γ-lyase promotes process of breast cancer in association with STAT3 signaling pathway. Oncotarget. 8:65677–65686. 2017. View Article : Google Scholar : PubMed/NCBI
54	Wang L, Shi H, Liu Y, Zhang W, Duan X, Li M, Shi X and Wang T: Cystathionine-γ-lyase promotes the metastasis of breast cancer via the VEGF signaling pathway. Int J Oncol. 55:473–487. 2019.PubMed/NCBI
55	Hanaoka K, Sasakura K, Suwanai Y, Toma-Fukai S, Shimamoto K, Takano Y, Shibuya N, Terai T, Komatsu T, Ueno T, et al: Discovery and mechanistic characterization of selective inhibitors of H₂S-producing enzyme: 3-Mercaptopyruvate sulfurtransferase (3MST) targeting active-site cysteine persulfide. Sci Rep. 7:402272017. View Article : Google Scholar : PubMed/NCBI
56	Nagahara N: Regulation of mercaptopyruvate sulfurtransferase activity via intrasubunit and intersubunit redox-sensing switches. Antioxid Redox Signal. 19:1792–1802. 2013. View Article : Google Scholar : PubMed/NCBI
57	Módis K, Asimakopoulou A, Coletta C, Papapetropoulos A and Szabo C: Oxidative stress suppresses the cellular bioenergetic effect of the 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway. Biochem Biophys Res Commun. 433:401–407. 2013. View Article : Google Scholar : PubMed/NCBI
58	Jeddi S, Gholami H, Gheibi S, Kashfi K and Ghasemi A: Altered gene expression of hydrogen sulfide-producing enzymes in the liver and muscles tissues of hyperthyroid rats. J Cell Physiol. 234:17937–17945. 2019. View Article : Google Scholar : PubMed/NCBI
59	Huang CW and Moore PK: H2S synthesizing enzymes: Biochemistry and molecular aspects. Handb Exp Pharmacol. 230:3–25. 2015. View Article : Google Scholar : PubMed/NCBI
60	Li M, Xu C, Shi J, Ding J, Wan X, Chen D, Gao J, Li C, Zhang J, Lin Y, et al: Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway. Gut. 67:2169–2180. 2018. View Article : Google Scholar : PubMed/NCBI
61	Augsburger F and Szabo C: Potential role of the 3-mercaptopyruvate sulfurtransferase (3-MST)-hydrogen sulfide (H₂S) pathway in cancer cells. Pharmacol Res. 154:1040832020. View Article : Google Scholar : PubMed/NCBI
62	Sen S, Kawahara B, Gupta D, Tsai R, Khachatryan M, Roy-Chowdhuri S, Bose S, Yoon A, Faull K, Farias-Eisner R and Chaudhuri G: Role of cystathionine β-synthase in human breast cancer. Free Radic Biol Med. 86:228–238. 2015. View Article : Google Scholar : PubMed/NCBI
63	Sen S, Kawahara B, Mahata SK, Tsai R, Yoon A, Hwang L, Hu-Moore K, Villanueva C, Vajihuddin A, Parameshwar P, et al: Cystathionine: A novel oncometabolite in human breast cancer. Arch Biochem Biophys. 604:95–102. 2016. View Article : Google Scholar : PubMed/NCBI
64	Kraus JP, Oliveriusová J, Sokolová J, Kraus E, Vlcek C, de Franchis R, Maclean KN, Bao L, Bukovsk, Patterson D, Paces V, et al: The human cystathionine beta-synthase (CBS) gene: Complete sequence, alternative splicing, and polymorphisms. Genomics. 52:312–324. 1998. View Article : Google Scholar : PubMed/NCBI
65	Tsai MY, Bignell M, Yang F, Welge BG, Graham KJ and Hanson NQ: Polygenic influence on plasma homocysteine: Association of two prevalent mutations, the 844ins68 of cystathionine beta-synthase and A(2756)G of methionine synthase, with lowered plasma homocysteine levels. Atherosclerosis. 149:131–137. 2000. View Article : Google Scholar : PubMed/NCBI
66	Weiner AS, Boyarskikh UA, Voronina EN, Selezneva IA, Sinkina TV, Lazarev AF, Petrova VD and Filipenko ML: Polymorphisms in the folate-metabolizing genes MTR, MTRR, and CBS and breast cancer risk. Cancer Epidemiol. 36:e95–e100. 2012. View Article : Google Scholar : PubMed/NCBI
67	Stevens VL, McCullough ML, Pavluck AL, Talbot JT, Feigelson HS, Thun MJ and Calle EE: Association of polymorphisms in one-carbon metabolism genes and postmenopausal breast cancer incidence. Cancer Epidemiol Biomarkers Prev. 16:1140–1147. 2007. View Article : Google Scholar : PubMed/NCBI
68	Gallegos-Arreola MP, Figuera-Villanueva LE, Ramos-Silva A, Salas-González E, Puebla-Pérez AM, Peralta-Leal V, García-Ortiz JE, Dávalos-Rodríguez IP and Zúñiga-González GM: The association between the 844ins68 polymorphism in the CBS gene and breast cancer. Arch Med Sci. 10:1214–1224. 2014. View Article : Google Scholar : PubMed/NCBI
69	Ryu CS, Kwak HC, Lee JY, Oh SJ, Phuong NT, Kang KW and Kim SK: Elevation of cysteine consumption in tamoxifen-resistant MCF-7 cells. Biochem Pharmacol. 85:197–206. 2013. View Article : Google Scholar : PubMed/NCBI
70	Ryu CS, Kwak HC, Lee KS, Kang KW, Oh SJ, Lee KH, Kim HM, Ma JY and Kim SK: Sulfur amino acid metabolism in doxorubicin-resistant breast cancer cells. Toxicol Appl Pharmacol. 255:94–102. 2011. View Article : Google Scholar : PubMed/NCBI
71	Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A, Eaton JW, Telang S and Chesney J: Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res. 10:R842008. View Article : Google Scholar : PubMed/NCBI
72	Chao C, Zatarain JR, Ding Y, Coletta C, Mrazek AA, Druzhyna N, Johnson P, Chen H, Hellmich JL, Asimakopoulou A, et al: Cystathionine-beta-synthase inhibition for colon cancer: Enhancement of the efficacy of aminooxyacetic acid via the prodrug approach. Mol Med. 22:361–379. 2016. View Article : Google Scholar : PubMed/NCBI
73	Hellmich MR, Coletta C, Chao C and Szabo C: The therapeutic potential of cystathionine β-synthetase/hydrogen sulfide inhibition in cancer. Antioxid Redox Signal. 22:424–448. 2015. View Article : Google Scholar : PubMed/NCBI
74	Asimakopoulou A, Panopoulos P, Chasapis CT, Coletta C, Zhou Z, Cirino G, Giannis A, Szabo C, Spyroulias GA and Papapetropoulos A: Selectivity of commonly used pharmacological inhibitors for cystathionine β synthase (CBS) and cystathionine γ lyase (CSE). Br J Pharmacol. 169:922–932. 2013. View Article : Google Scholar : PubMed/NCBI
75	Zhou Y, Yu J, Lei X, Wu J, Niu Q, Zhang Y, Liu H, Christen P, Gehring H and Wu F: High-throughput tandem-microwell assay identifies inhibitors of the hydrogen sulfide signaling pathway. Chem Commun. 49:11782–11784. 2013. View Article : Google Scholar
76	Wang L, Cai H, Hu Y, Liu F, Huang S, Zhou Y, Yu J, Xu J and Wu F: A pharmacological probe identifies cystathionine β-synthase as a new negative regulator for ferroptosis. Cell Death Dis. 9:10052018. View Article : Google Scholar : PubMed/NCBI
77	Zuhra K, Augsburger F, Majtan T and Szabo C: Cystathionine-β-synthase: Molecular regulation and pharmacological inhibition. Biomolecules. 10:6972020. View Article : Google Scholar
78	Marechal D, Brault V, Leon A, Martin D, Lopes Pereira P, Loaëc N, Birling MC, Friocourt G, Blondel M and Herault Y: Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of down syndrome and interacts genetically with Dyrk1a. Hum Mol Genet. 28:1561–1577. 2019. View Article : Google Scholar : PubMed/NCBI
79	Chen D, Cui QC, Yang H and Dou QP: Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 66:10425–10433. 2006. View Article : Google Scholar : PubMed/NCBI
80	Safi R, Nelson ER, Chitneni SK, Franz KJ, George DJ, Zalutsky MR and McDonnell DP: Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res. 74:5819–5831. 2014. View Article : Google Scholar : PubMed/NCBI
81	Zha J, Chen F, Dong H, Shi P, Yao Y, Zhang Y, Li R, Wang S, Li P, Wang W and Xu B: Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-κB pathway inhibition. J Transl Med. 12:1632014. View Article : Google Scholar : PubMed/NCBI
82	Papaioannou M, Mylonas I, Kast RE and Brüning A: Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition. Oncoscience. 1:21–29. 2013. View Article : Google Scholar : PubMed/NCBI
83	Cong J, Wang Y, Zhang X, Zhang N, Liu L, Soukup K, Michelakos T, Hong T, DeLeo A, Cai L, et al: A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Cancer Lett. 409:9–19. 2017. View Article : Google Scholar : PubMed/NCBI
84	Malcolm R, Olive MF and Lechner W: The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: Guidance for clinical practice. Expert Opin Drug Saf. 7:459–472. 2008. View Article : Google Scholar : PubMed/NCBI
85	Jiao Y, Hannafon BN and Ding WQ: Disulfiram's anticancer activity: Evidence and mechanisms. Anticancer Agents Med Chem. 16:1378–1384. 2016. View Article : Google Scholar : PubMed/NCBI
86	DeVito EE, Babuscio TA, Nich C, Ball SA and Carroll KM: Gender differences in clinical outcomes for cocaine dependence: Randomized clinical trials of behavioral therapy and disulfiram. Drug Alcohol Depend. 145:156–167. 2014. View Article : Google Scholar : PubMed/NCBI
87	Feng J, Weitner M, Shi W, Zhang S, Sullivan D and Zhang Y: Identification of additional anti-persister activity against Borrelia burgdorferi from an FDA drug library. Antibiotics (Basel). 4:397–410. 2015. View Article : Google Scholar : PubMed/NCBI
88	Thorson MK, Majtan T, Kraus JP and Barrios AM: Identification of cystathionine β-synthase inhibitors using a hydrogen sulfide selective probe. Angew Chem Int Ed Engl. 52:4641–4644. 2013. View Article : Google Scholar : PubMed/NCBI
89	Druzhyna N, Szczesny B, Olah G, Módis K, Asimakopoulou A, Pavlidou A, Szoleczky P, Gerö D, Yanagi K, Törö G, et al: Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer. Pharmacol. Res. 113:18–37. 2016.
90	Niu W, Wu P, Chen F, Wang J, Shang X and Xu C: Discovery of selective cystathionine β-synthase inhibitors by high-throughput screening with a fluorescent thiol probe. Medchemcomm. 8:198–201. 2016. View Article : Google Scholar : PubMed/NCBI
91	McCune CD, Chan SJ, Beio ML, Shen W, Chung WJ, Szczesniak LM, Chai C, Koh SQ, Wong PT and Berkowitz DB: ‘Zipped synthesis’ by cross-metathesis provides a cystathionine β-synthase inhibitor that attenuates cellular H2S levels and reduces neuronal infarction in a rat ischemic stroke model. ACS Central Sci. 2:242–252. 2016. View Article : Google Scholar
92	Sekiguchi F, Sekimoto T, Ogura A and Kawabata A: Endogenous hydrogen sulfide enhances cell proliferation of human gastric cancer AGS cells. Biol Pharm Bull. 39:887–890. 2016. View Article : Google Scholar : PubMed/NCBI
93	Hu Y, Wang L, Han X, Zhou Y, Zhang T, Wang L, Hong T, Zhang W, Guo XX, Sun J, et al: Discovery of a bioactive inhibitor with a new scaffold for cystathionine γ-lyase. J Med Chem. 62:1677–1683. 2019. View Article : Google Scholar : PubMed/NCBI
94	Bhattacharjee A, Sinha A, Ratia K, Yin L, Delgado-Rivera L, Petukhov PA, Thatcher GRJ and Wardrop DJ: 2-Arylidene hydrazinecarbodithioates as potent, selective inhibitors of cystathionine γ-lyase (CSE). ACS Med Chem Lett. 8:1241–1245. 2017. View Article : Google Scholar : PubMed/NCBI
95	Yadav PK, Vitvitsky V, Kim H, White A, Cho US and Banerjee R: S-3-Carboxypropyl-l-cysteine specifically inhibits cystathionine γ-lyase-dependent hydrogen sulfide synthesis. J Biol Chem. 294:11011–11022. 2019. View Article : Google Scholar : PubMed/NCBI
96	Wang L, Shi H, Zhang X, Zhang X, Liu Y, Kang W, Shi X and Wang T: I157172, a novel inhibitor of cystathionine γ-lyase, inhibits growth and migration of breast cancer cells via SIRT1-mediated deacetylation of STAT3. Oncol Rep. 41:427–436. 2019.PubMed/NCBI